Verona Pharma plc (NASDAQ:VRNA - Get Free Report) insider Kathleen A. Rickard sold 36,248 shares of the business's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $1.96, for a total transaction of $71,046.08. Following the sale, the insider now owns 2,621,552 shares of the company's stock, valued at approximately $5,138,241.92. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Verona Pharma Trading Down 0.4 %
Shares of NASDAQ:VRNA opened at $15.69 on Friday. Verona Pharma plc has a fifty-two week low of $11.83 and a fifty-two week high of $23.81. The firm's 50-day simple moving average is $16.23 and its 200-day simple moving average is $16.14. The company has a quick ratio of 33.33, a current ratio of 33.33 and a debt-to-equity ratio of 0.20.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. As a group, equities analysts predict that Verona Pharma plc will post -1.32 EPS for the current year.
Institutional Inflows and Outflows
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Institutional investors and hedge funds have recently bought and sold shares of the business. Cape Investment Advisory Inc. purchased a new stake in shares of Verona Pharma during the 4th quarter worth $40,000. Tower Research Capital LLC TRC boosted its holdings in Verona Pharma by 950.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,495 shares of the company's stock worth $89,000 after buying an additional 4,067 shares in the last quarter. Jump Financial LLC purchased a new stake in Verona Pharma during the fourth quarter worth about $226,000. Rathbones Group PLC grew its position in Verona Pharma by 66.7% during the third quarter. Rathbones Group PLC now owns 15,976 shares of the company's stock worth $260,000 after buying an additional 6,392 shares during the period. Finally, Matisse Capital purchased a new position in Verona Pharma in the first quarter valued at about $312,000. Institutional investors and hedge funds own 85.88% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on VRNA. Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Verona Pharma in a research report on Friday, March 1st. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price on shares of Verona Pharma in a report on Monday, March 4th. Finally, Piper Sandler raised their price target on Verona Pharma from $31.00 to $36.00 and gave the stock an "overweight" rating in a report on Tuesday, April 16th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $33.60.
Read Our Latest Research Report on VRNA
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
